As Parkinson’s cases continue to increase, the race remains in therapies to combat the effects of the disease, and researchers have pointed out an unlikely source of relief.
The psilocibine, a psychedelic compound found in some mushrooms, has been found to improve mood, cognition and motor symptoms in Parkinson’s patients, according to a new study by the University of California San Francisco (UCSF).
The substance, often called “magical mushrooms”, has been shown to relieve depression and anxiety, which prompted researchers to explore their potential for Parkinson.
Psychedelic Reported reports 183% of reserves, as health experts cite “disadvantage” of non -regulated use
People with neurological movement disorder often suffer from “weakening mood weakening dysfunction” and do not usually respond well to traditional antidepressants, according to a UCSF press statement.
Psilocibine, a psychedelic compound found in some mushrooms, has been found to improve mood, cognition and motor symptoms in Parkinson’s patients. (Istock)
“Many people do not realize this, but mood symptoms in Parkinson are related to faster physical decline,” said Ellen Bradley, MD, assistant professor and associate director of the UCSF translational psychedelic research program in the statement.
“And they are actually a stronger predictor of the quality of life of patients with Parkinson’s than their motor symptoms.”
The small study included 12 people with mild to moderate Parkinson’s disease. It ranged from 40 to 75 years. They all had depression and/or anxiety.
FDA rejects MDMA as a Psychedelic Mental Health Psychedelic Treatment, PTSD
All received a 10 mg psilocybin dose, then a dose of 25 mg two weeks later. To measure the effects, participants met with a licensed therapist before and after receiving the medication.
In one -week and one month’s follow -up, patients reported “clinically significant” clinical improvements “not only in the mood and cognition, but also the motor function.
“Many people do not realize this, but the symptoms of the mood in Parkinson are related to faster physical descent.”
“These results are really encouraging,” Bradley told Fox News Digital. “Depression and anxiety, which weaken so many people with Parkinson’s, improved significantly, and these improvements lasted at least three months after patients took the drug.”
Amir Inamdar, a pharmaceutical doctor in the United Kingdom and Cybin’s medical director, said that the improvement of motor symptoms was a bit surprising.
“As authors point out, this could be due to dopamine modulation by means of the effect of psilocibine on various types of serotonin receptors.” (Inamdar did not participate in the study.)
The most common side effects of the psilocybin were anxiety, nausea, headache and high blood pressure, but none was serious enough to require medical care, according to researchers.
People with neurological movement disorder often suffer from “weakening dysfunction of mood” and do not usually respond well to traditional antidepressants. (Istock)
“Despite the reports of challenging experiences in a couple of participants, the psilocibine seemed to be well tolerated,” said Inamdar. “The side effects were consistent with what has been seen in other studies, without precipitation/ exacerbation of psychotic symptoms.”
The study, published in Neuropsychopharmacology, a natural publication, was funded by an anonymous donor.
Limitations and more research
This was the first study to measure the effects of a psychedelic substance in patients with neurodegenerative disease, according to USCF.
While this study was a “first important step,” Bradley said that researchers could not draw conclusions, as it was a small pilot without a control group.
Click here to get the Fox News app
“We have now started a much larger trial designed to try rigorously if the psilocibine is effective in Parkison,” Fox News Digital told Fox.
“We also collect multimodal biological data to understand the functioning of the psilocibine. This is essential not only to optimize psilocibine treatments, but also to guide the development of next generation psychedelic that are in the pipeline now and could be promising for people with Parkinson.”
Click here to register -you are in our health newsletter
Bradley still recommends that Parkinson’s patients approach the psylocibine and other psychedelic with “very precaution”.
“I would not recommend my patients with Parkinson to start using psilocibine,” he said. “We are very, very soon in this research and we do not believe that these drugs will be safe for everyone with illness.”
This was the first study to measure the effects of a psychedelic substance in patients with neurodegenerative disease, according to USCF. (Istock)
“I hope people continue to defend research in order to accelerate this process to identify the right psychedelic treatment for the right patient at the right time.”
Inamadar agreed that while the results are encouraged, the study was based on a small and limited sample.
For more health items, visit www.foxnews.com/health
“The study was also open marking, which is provided for higher hope effects, although improvements in mood and anxiety symptoms were still seen at three months,” he added.
“Overall, [the] The very encouraging results justify additional research, certainly to try to understand the mechanism in improving motor symptoms. “
#Parkinsons #patients #magic #mushrooms #key #advantages #findings #study
Image Source : www.foxnews.com